More on PPHM

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings
- Holders

Financials

Income Statement
Balance Sheet
Cash Flow Statement

Upcoming Events

- Earnings (N/A)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

PEREGRINE PHARMA (NQ:PPHM)
Delayed: 1.73 --0 (-0%)
Trade Now!
Previous Close $1.73    52 Week High $2.43 
Open $4272.11    52 Week Low $1.11 
Day High $1.73    P/E N/A 
Day Low $1.73    EPS $-0.50 
Volume      

Friends, Peers and Foes (?): NHLD, POWR, PPBI, PRTA, PLPM (more...)

Apr 9, 2014 11:00 AM Data Presented at AACR Support Potential of Peregrine's PS-Targeting Immunotherapy Bavituximab to Enhance Anti-Tumor and Immune-Stimulating Effects of Anti-CTLA-4 and Anti-PD-1 Treatments in Mode
Apr 7, 2014 09:28 AM Pre-Open Stock Movers 4/7: (VOCS) (QCOR) (AGIO) Higher; (GNK) (MNKD) (DDD) Lower (more...)
Apr 7, 2014 08:00 AM Data Presented at AACR Support Potential of Combining Peregrine's PS-Targeting Immunotherapy Agent Bavituximab With Irradiation in Lung Cancer
Apr 1, 2014 04:00 PM Peregrine Pharmaceuticals Announces Three Abstracts Accepted for Presentation at AACR 2014 Annual Meeting
Mar 14, 2014 02:14 PM Roth Reaffirms Peregrine Pharma (PPHM) at Buy; Prelim. Bavituximab + Sorafenib Phase I/II is Positive
Mar 14, 2014 08:00 AM Presentation at Annual Society of Surgical Oncology Meeting Updates Progress in Investigator-Sponsored Phase i/ii Trial of Peregrine's Bavituximab in Combination With Sorafenib in Liver Cancer
Mar 13, 2014 08:00 AM Preclinical Data Presentations at Keystone Symposia Highlight Broad Immunotherapy Potential of Peregrine Pharmaceuticals' PS-Targeting Antibodies
Mar 11, 2014 04:21 PM Form 8-K PEREGRINE PHARMACEUTICAL For: Mar 11
Mar 11, 2014 04:10 PM Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
Mar 11, 2014 08:00 AM Data Presentations at Keystone Symposium Support Potential of Peregrine Pharmaceuticals' PS-Targeting Antibodies to Overcome Immune Suppression and Enhance Anti-Tumor Activity of Anti-CTLA-4 and
View All Articles